Arena Pharmaceuticals (FRA:RN3N) EBIT per Share : €-8.78 (TTM As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals EBIT per Share?

Arena Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2021 was €-2.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2021 was €-8.78.

During the past 3 years, the average EBIT per Share Growth Rate was -43.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Arena Pharmaceuticals's EBIT per Share or its related term are showing as below:

FRA:RN3N' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.2 Med: 6.25 Max: 537.7
Current: -43.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arena Pharmaceuticals was 537.70% per year. The lowest was -53.20% per year. And the median was 6.25% per year.

FRA:RN3N's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.7 vs FRA:RN3N: -43.60

Arena Pharmaceuticals's EBIT for the three months ended in Dec. 2021 was €-136.83 Mil.

Arena Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Arena Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals EBIT per Share Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-2.05

-2.49

8.93

-6.01

-8.92

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
EBIT per Share	Get a 7-Day Free Trial															-1.71	-1.86	-1.98	-2.72	-2.23

Arena Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Arena Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-541.862	/	60.776
=	-8.92

Arena Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2021 is calculated as

	EBIT per Share		(Q: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-136.826	/	61.382
=	-2.23

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.78

Arena Pharmaceuticals (FRA:RN3N) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Arena Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines